"These milestones, observations and other market indicators suggest that there may be significant opportunity to drive revenue growth from increased adoption and sales of our galectin-3 test. To this end, we have prioritized our actions and investments around what we believe to be key drivers of adoption and revenue growth in the US and EU, including reimbursement and the automated versions of our tests. In so doing, we will redirect our effort and investments from the previously announced CLIA laboratory, launch of CardioSCORE in Europe (except as partnership opportunities arise), and longer term clinical studies so that we may further develop and support the message, the product and the product features that are required to drive the adoption of galectin-3 testing."
FOR THIS???? I am rather disappointed for 2 landmark decisions in a weeks time. This should be running regardless of no money changing hands. Every morning there are stocks that open 2-3-4 dollars over previous closing and they are not halted . GLTA
What a strange trading series, but it seems they have several galectin 3 test that looks #$%$ preventive testing for other ailments. BGMD'S seems to be a after the event test.
If the judge were to allow that,(he won't) then the judge should let the infringement time line go all the way back to 2007 (which should have been the starting point) cause that how long Google's really been infringing. The laches ruling was a farce too! JMO
it should lead you to a very interesting read.
Sentiment: Strong Buy
Type in a search bar,,, '''Why Google Might Be Going to $0'' and read the story by James Altucher. great read..